An interventional study of Cetirizine (Zyrtec) and Latanoprost in Microneedling-Assisted Delivery, Cetirizine and Latanoprost, sponsored by Tanta University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Alopecia Areata with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Alopecia Areata · Egypt.
Among the 31 studies in Alopecia Areata with a site in Egypt, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2022, is one of 14 with no phase, and was the 31st registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →7 of the 31 studies in Alopecia Areata with a site in Egypt are open now. Recruiting first, the newest first:
Egymedicalpedia · Sites in Egypt
Ages 30–35
Zagazig University · Sites in Egypt
Ages 16+
Sohag University · Sites in Egypt
Ages 4+
Assiut University · Sites in Egypt
Ages 6–60
Al-Azhar University · Sites in Egypt
Ages 12+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 3 · Phase 4 6
First in 2012; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 50 across the 29 interventional studies, 120 across the 2 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 31 have an industry lead sponsor. The 10 most frequent:
Tanta University is the lead sponsor of 1,013 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Tanta University has 1 study filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
2 of the studies in Alopecia Areata with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06327581Zagazig UniversityCombined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata | 2026-12-30 |
| NCT06399783Assiut UniversityTopical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Alopecia Areata with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.
Alopecia areata (AA) is a chronic inflammatory disease affecting the hair follicles with a possible multifactorial origin, most prominently in genetically predisposed patients. It is a common cause of non scarring hair loss that presents in a patchy, confluent, or diffuse pattern. The onset may be at any age and there is no known race or sex preponderance.
The treatment of AA depends on the severity and extent of the disease. Treatment options include topical or intralesional corticosteroids, phototherapy, topical irritants, topical minoxidil, topical tacrolimus, topical vitamin D analogs and platelet rich plasma injection. For resistant cases, psoralen with ultraviolet A light, oral cyclosporine and other immunosuppressants could be beneficial.
Microneedling therapy is becoming popular in management of acne scars and also for facial rejuvenations. Recently it has been shown to stimulate hair growth. The proposed mechanism of action is thought to be stimulation of dermal papilla and stem cells and also increasing the blood supply to the hair follicles.
Scalp microneedling is a minimally invasive procedure in which various micro-channels are created by short fine needles to help in penetration and absorption of various agents into the skin. So, microneedling is a promising and effective therapy for the treatment of AA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with microneedling-aided administration of topical cetirizine 1% solution.
Drug: Cetirizine (Zyrtec)
Patients treated with microneedling-aided administration of topical latanoprost 0.01% solution.
Drug: Latanoprost
Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group
Drug: Triamcinolone Acetonide
Patients treated with microneedling only as a negative control group
Procedure: Microneedling only
Patinets treated with microneedling-aided administration of topical cetirizine 1% solution
Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group
Patients treated with microneedling-aided administration of topical triamcinolone acetonide (TrA) (10mg/ml) as a positive control group
Patientstreated with microneedling only as a negative control group
Severity of Alopecia Tool Score (SALT Score)
The Severity of Alopecia Tool (SALT) score was used to assess the extent of scalp hair loss. The score ranges from 0 to 100, with higher scores indicating greater scalp hair loss. Changes in SALT score from baseline was compared between the treatment groups.
Time frame: Baseline and 12 weeks
Global assessment of hair regrowth
Hair regrowth was evaluated by the investigator using standardized clinical photographs and a global assessment scale. The degree of hair regrowth was graded on a 5-point scale ranging from 0 (no regrowth) to 4 (excellent regrowth, ≥75%), with higher scores indicating greater clinical improvement. Assessments were performed at baseline and at the end of the 12-week treatment period.
Time frame: Baseline and at the end of the 12-week treatment period
Adverse events
Complications, including pain, erythema, edema, pruritus, infection, post-inflammatory hyperpigmentation, allergic reactions, and any other local or systemic adverse events
Time frame: Throughout the 12-week study period.
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Oct 2024, 24 months.
Of 21 interventional studies with no phase under Alopecia Areata, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetirizine · Latanoprost